Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Purevax Rabies   
Auth. number : EU/2/10/117
Active substance : Rabies recombinant canarypox virus (vCP65)
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AX - Other immunologicals
Chemical substance: QI06AX - Other immunologicals
(See WHO ATCvet Index)
Indication: Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, 69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/02/2011 Centralised - Authorisation EMEA/V/C/2003 (2011)1147 of 18/02/2011
03/08/2011 Centralised - Variation EMEA/V/C/2003/IB/1
Updated with Decision(2012)1178 of 17/02/2012
21/02/2012 Centralised - Variation (2012)1178 of 17/02/2012
13/03/2012 Centralised - Variation EMEA/V/C/2003/II/2 (2012)1735 of 09/03/2012
04/12/2015 Centralised - Renewal EMEA/V/C/2003/R/4 (2015)8817 of 02/12/2015
02/05/2016 Corrigendum (2016)8817 of 02/12/2015